NCT00798902View on ClinicalTrials.gov

Pilot Study to Assess Safety/Preliminary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2012

Study Completion Date

October 31, 2012

Conditions
Degenerative Disc DiseaseSpondylolisthesis
Interventions
DEVICE

Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules

150 micrograms/cc BVF

OTHER

Iliac crest autograft

autograft

Trial Locations (6)

13790

Confidential, Johnson City

20037

Confidential, Washington D.C.

65101

Confidential, Jefferson City

66160

University of Kansas Medical Center, Kansas City

75701

Confidential, Tyler

81301

Confidential, Durango

Sponsors
All Listed Sponsors
lead

BioSurface Engineering Technologies, Inc

INDUSTRY